Independent Research Group Validates Market Demand of VisionGate’s Two ProductsContinue reading
Category Archives: AZBio News
TGen investigates global fungal threat; discovers six new species associated with bat evolution
Histoplasma infection poses deadly risk to HIV and other immune-compromised patientsContinue reading
Explore the Neuron Forest and Discover Arizona Opportunities in the Arizona Pavilion at BIO 2016
Rising above the Arizona Pavilion at the BIO International Convention, you will find picture-postcard vistas of Arizona’s natural wonders.
Inside the Arizona Pavilion, visitors have the opportunity to explore new vistas as they take a virtual reality journey inside the human brain, meet with award winning life science innovators, and learn about a wide range of Arizona opportunities.Continue reading
UA Researcher Kacey Ernst Maps Potential Risk Areas for Zika
Kacey Ernst testifies before a U.S. House subcommittee, saying that a recent study expects the Aedes aegypti mosquito to increase in numbers across the South and East. Continue reading
Bill to Streamline CMS’s Process for Breakthrough Technologies Introduced in the US Senate
The Ensuring Patient Access to Critical Breakthrough Products Act, will help bridge a gap between FDA and CMS and improve patient access to breakthrough medical technologies for serious illnesses, S. 2998, to expedite CMS decision-making for innovative medical technologies.Continue reading
The biopharmaceutical sector had nearly $10B economic impact in Arizona
Republished with permission from the Phoenix Business Journal. All Rights Reserved Source
The biopharmaceutical industry is a major contributor to the U.S. economy, and also has a growing presence in Arizona, according to a new report released by TEConomy Partners LLC.
Since 2000, members companies of PhRMA have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.Continue reading
Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients
PHOENIX, May 24, 2016 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that it has successfully completed its Phase 1/Phase 2 safety and pharmacokinetic (PK) study in pediatric subjects with treatment-resistant epilepsy.Continue reading
The Fostering Innovation Act Passes in the U.S. House of Representatives
Sinema, Fitzpatrick Jobs Bill Passes House
Revolutionary organ-on-a-chip device mimics human gut action
Pioneering research tool developed at UA College of Medicine – PhoenixContinue reading
Arizona Governor Ducey Signs Bill Ensuring Patient Access to Interchangeable Biologic Medicines
Communication Important for Patients and PhysiciansContinue reading